Log in to search using one of your social media accounts:

 

Celebrity doctor warns we should wear toxic sunscreen while talking on our cellphone or using our computer

(Natural News) The fear of getting skin cancer drives many people to wear sunscreen every time they leave the house, even if their plans don’t include spending time outdoors. The sunscreen industry has embraced this line of thinking, which is one big reason that Vitamin D deficiencies are soaring in this country. Melanoma is certainly...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news

Related Links:

Publication date: 15 September 2018 Source:Journal of Molecular Structure, Volume 1168 Author(s): Monika Kadela-Tomanek, Bartosz Pawełczak, Maria Jastrzębska, Ewa Bębenek, Elwira Chrobak, Małgorzata Latocha, Joachim Kusz, Maria Książek, Stanisław Boryczka 6,7-Dichloro-2-methyl-5,8-quinolinedione was investigated using different experimental methods as well as a variety of various quantum chemical calculations in order to characterize its molecular structure as a potential anticancer active compound. We used X-ray diffraction, IR spectrum analysis supplemented by the density functional theory (DFT) calculations, mol...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Authors: Decaudin D, El Botty R, Diallo B, Massonnet G, Fleury J, Naguez A, Raymondie C, Davies E, Smith A, Wilson J, Howes C, Smith PD, Cassoux N, Piperno-Neumann S, Roman-Roman S, Némati F Abstract The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have raised hopes of more effective, targeted therapies, based on MEK inhibition, for example. We evaluated the potential of drug combinations to increase the efficacy of the MEK inhibitor selumetinib (AZD6244, ARRY-142886),...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSION: This study has defined the rate of cSCC in a large, well defined New Zealand population, and estimated age and ethnicity adjusted incidence in New Zealand. It has demonstrated the highest incidence of cSCC in the world outside Australia. Overall positive margin rate of excised lesions was acceptable. PMID: 29771903 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Publication date: Available online 18 May 2018 Source:Reports of Practical Oncology & Radiotherapy Author(s): Cecilia Orbegoso, Krithika Murali, Susana Banerjee Background Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney cancer, lung cancer and most recently, tumours with microsatellite instability. There is much enthusiasm for investigating this approach in gynaecological cancers and the possibility that immunotherapy might become part of the therapeutic landscape for gynaecological malignancies. Cervica...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
The BMJScan (at two resolutions) of a category 3 melanoma in situ.FINDINGSIn a new study, researchers have developed updated guidelines for classifying a serious form of skin cancer called invasive melanoma. The American Joint Committee on Cancer, an organization that provides information on “cancer staging,” or the severity of individual cases of cancer, recently updated its guidelines for melanoma. The researchers found that when pathologists used the new guidelines for cases of early stage invasive melanoma, they agreed with an expert-defined diagnosis 10 percent more often.METHODIn the study, researchers re...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Researchers have updated the guidelines for determining the severity of individual cases of a type of serious skin cancer known as invasive melanoma.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Phase III trials with ipilimumab showed an improved survival in patients with metastatic melanoma. We evaluated the use and safety of ipilimumab, and the survival of all patients with metastatic cutaneous melanoma (N=807) receiving ipilimumab in real-world clinical practice in The Netherlands using data from the Dutch Melanoma Treatment Registry. Patients who were registered between July 2012 and July 2015 were included and analyzed according to their treatment status: treatment-naive (N=344) versus previously-treated (N=463). Overall, 70% of treatment-naive patients and 62% of previously-treated patients received all four...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
In conclusion, this nation-wide study provides valuable insights into the healthcare costs of advanced cutaneous melanoma patients who were treated with ipilimumab in clinical practice. Most of the costs were attributable to ipilimumab, but the costs and its distribution varied considerably across subgroups.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
Authors: Gagat M, Krajewski A, Grzanka D, Grzanka A Abstract Cyclin F is a part of the Skp, Cullin, F-box containing ligase complex. The activity of cyclin F includes cell cycle control, centrosome duplication and response to DNA damage. The cyclin F expression pattern is very similar to cyclin A, but cyclin F is an orphan cyclin without its cyclin-dependent kinase partner. There is little evidence concerning the role of cyclin F in cancer. In the present study, for the first time, we present analysis from The Cancer Genome Atlas (TCGA) data in the context of expression of cyclin F mRNA in melan...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Fu X, Tao L, Wang PY, Cripe TP, Zhang X Abstract Herpes simplex virus (HSV) is one of the many viruses that have been modified or adapted for oncolytic purposes. There are two serotypes of HSV, HSV-1 and HSV-2. The majority of oncolytic HSVs, including T-VEC which has recently been approved by the US Food and Drug Administration (FDA) for clinical use in treating late stage melanoma patients, are derived from HSV-1. Recently, we and others have developed several HSV-2 based oncolytic viruses. During our in vitro characterization of oncolytic viruses developed from both serotypes (Baco-1 from HSV-1 and FusO...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Computers | Melanoma | Skin | Skin Cancer | Toxicology | Vitamin D | Vitamins